TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37261839
Drug: Low-dose atropine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose atropine 0.01%
Study: 37262929
Drug: Saliva insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saliva insulin
Study: 37262961
Drug: Maintenance rucaparib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance rucaparib (600 mg twice daily)
Study: 37263673
Drug: KN046 administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: KN046 administered at doses of 1, 3, and 5 mg/kg every 2 weeks (Q2W), 5 mg/kg every 3 weeks (Q3W), and 300 mg Q3W.
Study: 37263683
Drug: High-dose oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose oral antibiotics
Study: 37263914
Drug: Mixed nuts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed nuts (42.5 g/day)
Study: 37264143
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (pre- and postprocedural intravenous hydration)
Study: 37264295
Drug: Orsiro Mission
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Orsiro Mission stent with 1-month dual antiplatelet therapy (DAPT)
Study: 37264295
Drug: Resolute Onyx
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Resolute Onyx stent with 1-month dual antiplatelet therapy (DAPT)
Study: 37264321
Drug: Radiotherapy ± chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy ± chemotherapy
Study: 37264321
Drug: Trans-Oral Robotic
Normalized name: Rezyst Probiotic Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trans-Oral Robotic Surgery (TORS)
Study: 37264993
Drug: Adalimumab (subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab (subcutaneous administration at doses following the package insert)
Study: 37265222
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of aerobic training and semaglutide treatment
Study: 37265259
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of lenacapavir plus teropavimab and zinlirvimab
Study: 37265425
Drug: INBRX-109 (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: INBRX-109 (3 mg/kg every 3 weeks)
Study: 37265820
Drug: Long-term β-blocker
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term β-blocker therapy
Study: 37265820
Drug: No β-blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: No β-blocker treatment
Study: 37266942
Drug: Bevacizumab (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab (15 mg/kg) with standard chemoradiation (cisplatin 100 mg/m2, RT 69.96 Gy) followed by adjuvant bevacizumab (15 mg/kg) with cisplatin (80 mg/m2) and fluorouracil (1000 mg/m2/d)
Study: 37266940
Drug: Targeted quality
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted quality improvement intervention for IV rtPA administration in secondary hospitals
Study: 37266943
Drug: Bisensory treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisensory treatment (combined auditory and somatosensory) for 30 minutes per day for 6 weeks
Study: 37266943
Drug: Auditory-only treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Auditory-only treatment for 30 minutes per day for 6 weeks
Study: 37267169
Drug: Managing substance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Managing substance use and treatment of OUD
Study: 37267394
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg Melatonin orally daily for two consecutive menstrual cycles
Study: 37267394
Drug: Placebo orally
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo orally daily for two consecutive menstrual cycles
Study: 37267720
Drug: Serum metabolome,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum metabolome, adiponectin, inflammatory markers, and insulin-like growth factor-binding protein-1 phosphoisoforms analyzed at GDM diagnosis
Study: 37267720
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of IDL cholesterol, early gestational weight gain, fasting and 2-h glucose from oral glucose tolerance test
Study: 37267804
Drug: GM-CSF 125
Normalized name: axatilimab-csfr
Approvals — FDA: no, EMA: no, PMDA: no
Description: GM-CSF 125 μg/m
Study: 37268010
Drug: More intensive
Normalized name: polyurethane-35 (not more than MPA.S at 40 %)
Approvals — FDA: no, EMA: no, PMDA: no
Description: More intensive cryotherapy treatment
Study: 37268157
Drug: Atezolizumab subcutaneous
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab subcutaneous (SC) 1875 mg
Study: 37268157
Drug: Atezolizumab intravenous
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab intravenous (IV) 1200 mg
Study: 37268435
Drug: Elamipretide 40
Normalized name: Elamipretide
DrugBank: Elamipretide (DB11981)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elamipretide 40 mg/d for 24 weeks
Study: 37268656
Drug: Triheptanoin at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triheptanoin at maximum tolerable dose
Study: 37268772
Drug: Medication dose
Normalized name: Medicated Shampoo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication dose
Study: 37268802
Drug: Face mask
Normalized name: CVS Face Masks
Approvals — FDA: no, EMA: no, PMDA: no
Description: Face mask oxygen therapy
Study: 37269076
Drug: GSK3739937 (GSK'937)
Normalized name: GSK-239512
DrugBank: GSK-239512 (DB15120)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3739937 (GSK'937) - single doses of 10-800 mg
Study: 37269076
Drug: GSK3739937 (GSK'937)
Normalized name: GSK-239512
DrugBank: GSK-239512 (DB15120)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3739937 (GSK'937) - multiple doses of 25-100 mg once daily or 500 mg once weekly
Study: 37269076
Drug: GSK3739937 (GSK'937)
Normalized name: GSK-239512
DrugBank: GSK-239512 (DB15120)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3739937 (GSK'937) - bioavailability as a tablet versus powder-in-bottle
Study: 37269344
Drug: Brigimadlin (BI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brigimadlin (BI 907828) at a maximum tolerated dose of 60 mg for D1q3w and 45 mg for D1D8q4w
Study: 37269841
Drug: Lutetium-177 PSMA-targeted
Normalized name: Lutetium dotatate Lu-177
DrugBank: Lutetium Lu 177 dotatate (DB13985)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lutetium-177 PSMA-targeted radioligand therapy
Study: 37269870
Drug: Nangibotide 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nangibotide 0.3 mg/kg per h (low-dose group)
Study: 37269870
Drug: Nangibotide 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nangibotide 1.0 mg/kg per h (high-dose group)
Study: 37269870
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (placebo, low-dose, high-dose)
Study: 37269909
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose blueberry powder (2.5%)
Study: 37269909
Drug: Medium dose
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium dose blueberry powder (5%)
Study: 37269941
Drug: Group A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A: 0.5 mg/kg once daily for 14 days
Study: 37269941
Drug: Group B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B: 1 mg/kg once daily for 7 days
Study: 37269941
Drug: Group C:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C: 1 mg/kg twice daily for 3.5 days
Study: 37270027
Drug: Breastfeeding with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breastfeeding with at least 1 daily meal of Cows' Milk Formula (CMF)
Study: 37270188
Drug: Eye-movement desensitisation
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eye-movement desensitisation and reprocessing therapy (EMDR) plus standard neuropsychiatric care (NPC)
Study: 37270201
Drug: Routine data
Normalized name: NO DATA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine data (Aspirin)
Study: 37270289
Drug: Teduglutide 0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teduglutide 0.05 mg/kg/d for 48 weeks
Study: 37270471
Drug: Myofascial release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myofascial release therapy (MRT)
Study: 37270517
Drug: Sertraline 50
Normalized name: sertraline 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline 50 mg twice daily for 8 weeks
Study: 37270698
Drug: Tepotinib, 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tepotinib, 500 mg once daily
Study: 37271356
Drug: Preventive PCI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventive PCI plus optimal medical therapy (OMT)
Study: 37271412
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 3600 mg per day
Study: 37271416
Drug: 60-mg ferrous
Normalized name: ferrous fumarate 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60-mg ferrous sulfate
Study: 37271416
Drug: 18-mg ferrous
Normalized name: Ferrous Gluconate
DrugBank: Ferrous gluconate (DB14488)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 18-mg ferrous bisglycinate
Study: 37271706
Drug: Fourth dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fourth dose of NVX-CoV2373 (5 µg rS protein + 50 µg Matrix-M adjuvant)
Study: 37271706
Drug: Third dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Third dose of NVX-CoV2373
Study: 37271706
Drug: Fourth dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fourth dose of NVX-CoV2373
Study: 37271818
Drug: Ivermectin mass
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ivermectin mass drug administration to humans and/or livestock
Study: 37272513
Drug: Neoadjuvant pembrolizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant pembrolizumab (200 mg) plus cisplatin-based chemotherapy for 4 cycles, followed by surgery and adjuvant pembrolizumab (200 mg) for up to 13 cycles.
Study: 37272513
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus cisplatin-based chemotherapy for 4 cycles, followed by surgery and placebo for up to 13 cycles.
Study: 37272516
Drug: Vorasidenib (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vorasidenib (40 mg once daily)
Study: 37272521
Drug: Dupilumab (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dupilumab (300 mg) subcutaneously once every 2 weeks
Study: 37273224
Drug: Transdermal nitroglycerin
Normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal nitroglycerin (NTG) 0.2-0.6 mg/h
Study: 37273420
Drug: Ceralasertib monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceralasertib monotherapy 160 mg BID continuously
Study: 37273420
Drug: Acalabrutinib 100
Normalized name: acalabrutinib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acalabrutinib 100 mg BID followed by ceralasertib 160 mg BID 1 week on/3 weeks off
Study: 37273449
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg oral risedronate for six months
Study: 37273942
Drug: Ulotaront (25,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ulotaront (25, 50, or 75 mg/d)
Study: 37275963
Drug: Ribociclib (600-mg/day)
DrugBank: Ribociclib (DB11730)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ribociclib (600-mg/day)
Study: 37276067
Drug: Tislelizumab 200
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tislelizumab 200 mg every 3 weeks (Cohort 3)
Study: 37276067
Drug: Tislelizumab 200
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tislelizumab 200 mg every 3 weeks (Cohort 1)
Study: 37276067
Drug: Tislelizumab 200
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tislelizumab 200 mg every 3 weeks (Cohort 2)
Study: 37276451
Drug: Pegaspargase 2000
Normalized name: pegaspargase
DrugBank: Pegaspargase (DB00059)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pegaspargase 2000 IU/m2 added to courses 1, 2, 5, and 6 of an 8-block chemotherapy protocol.
Study: 37276451
Drug: Pegaspargase treatment
Normalized name: pegaspargase
DrugBank: Pegaspargase (DB00059)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pegaspargase treatment with allogeneic hematopoietic cell transplantation (HCT)
Study: 37276451
Drug: Pegaspargase treatment
Normalized name: pegaspargase
DrugBank: Pegaspargase (DB00059)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pegaspargase treatment
Study: 37276496
Drug: MS2003-SR (modified
Approvals — FDA: no, EMA: no, PMDA: no
Description: MS2003-SR (modified Berlin-Frankfurt-Muenster ALL-IC2002 protocol with 120 mg/m² anthracycline)
Study: 37276510
Drug: Treatment Choice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment Choice (TC) - azacitidine, decitabine, or low-dose cytarabine
Study: 37276510
Drug: Treatment Choice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment Choice (TC)
Study: 37276510
Drug: Treatment Choice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment Choice (TC) (in patients receiving ≥4 cycles)
Study: 37276871
Drug: Zanidatamab 20
Normalized name: Zanidatamab
DrugBank: Zanidatamab (DB15471)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zanidatamab 20 mg/kg intravenously every 2 weeks
Study: 37276913
Drug: Half-dose quadruple
Normalized name: propranolol hydrochloride Extended Release Oral Capsule [Half-Betadur CR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half-dose quadruple therapy (irbesartan 75 mg + metoprolol 23.75 mg + amlodipine 2.5 mg + indapamide 1.25 mg)
Study: 37276913
Drug: Standard-dose dual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose dual therapy (irbesartan 150 mg + amlodipine 5 mg)
Study: 37276947
Drug: Intravenous recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous recombinant follicle-stimulating hormone (rFSH) treatment
Study: 37277100
Drug: Standard reminiscence
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard reminiscence therapy
Study: 37277217
Drug: Intensive lipid
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive lipid lowering (LDL-C of <1.8 mmol/L or ≥50% reduction from the baseline)
Study: 37277217
Drug: Moderate-intensity lipid
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate-intensity lipid lowering (LDL-C of <2.6 mmol/L or 30%-49% reduction from the baseline)
Study: 37277219
Drug: Rhythm control
Normalized name: ALUMINUM ZIRCONIUM TRICHLOROHYDREX GLY 180 mg in 1 g TOPICAL STICK [ZUSKA RHYTHM]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhythm control therapies
Study: 37277454
Drug: Camonsertib (RP-3500)
Normalized name: Camonsertib
DrugBank: Camonsertib (DB18888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camonsertib (RP-3500) at a recommended phase 2 dose of 160 mg weekly on days 1-3
Study: 37277703
Drug: Erector spinae
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erector spinae plane block (ESPB) with 20 ml of bupivacaine 0.25% (n=50)
Study: 37277703
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with 20 ml saline injection (n=50)
Study: 37278638
Drug: Intraplantar injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraplantar injection of cancer exosomes
Study: 37278760
Drug: Integrating sublingual
Normalized name: mecobalamin 1000 MCG Disintegrating Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrating sublingual microcirculatory perfusion variables in the therapy plan
Study: 37278858
Drug: Metformin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin plus low-dose temozolomide (50 mg/m²)
Study: 37278858
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus low-dose temozolomide (50 mg/m²)
Study: 37278879
Drug: Adavosertib (AZD1775)
Normalized name: Adavosertib
DrugBank: Adavosertib (DB11740)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adavosertib (AZD1775) 175 mg orally twice a day on days 1-3 and 8-10 of a 21-day treatment cycle
Study: 37278968
Drug: D-galactose supplementation
Normalized name: D(+)-Galactose
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-galactose supplementation (1.5 g/kg/day for 6 months)
Study: 37278972
Drug: GB223 (7,
Approvals — FDA: no, EMA: no, PMDA: no
Description: GB223 (7, 21, 63, 119, or 140 mg)
Study: 37278999
Drug: Peer health
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peer health coaching intervention for 12 months with educational materials, automatic blood pressure monitor, scale, pill organizer, and healthy nutrition tools.
Study: 37279000
Drug: Ticagrelor-aspirin (180-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticagrelor-aspirin (180-mg loading dose on day 1 followed by 90 mg twice daily for days 2-90)
Study: 37279000
Drug: Clopidogrel-aspirin (300-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel-aspirin (300-mg loading dose on day 1 followed by 75 mg/d for days 2-90)
Study: 37279000
Drug: Ticagrelor-aspirin among
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor-aspirin among poor metabolizers
Study: 37279000
Drug: Clopidogrel-aspirin among
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel-aspirin among poor metabolizers
Study: 37279034
Drug: New insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: New insulin pump
Study: 37279301
Drug: Riluzole (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Riluzole (100 mg BID for 24 hours, then 50 mg BID for 13 days)
Study: 37279602
Drug: Oral camostat
Normalized name: collagen hemostat
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral camostat for 7 days
Study: 37279641
Drug: MMM CBT
Normalized name: guaifenesin
DrugBank: Guaifenesin (DB00874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MMM CBT treatment (9-13 sessions)
Study: 37279709
Drug: Caffeine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (2.5 mg/kg, twice over 24 h)
Study: 37279797
Drug: ONC201 (625
Approvals — FDA: no, EMA: no, PMDA: no
Description: ONC201 (625 mg weekly)
Study: 37279836
Drug: Degradable Hydrogel
Normalized name: Hydrogen
DrugBank: Hydrogen (DB15127)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Degradable Hydrogel for sustained localized delivery of anti-tumor drugs; specific dosage and duration not mentioned.
Study: 37279836
Drug: Direct intratumoral
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct intratumoral injection of a drug; specific dosage and duration not mentioned.
Study: 37279855
Drug: Urinary-derived human
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urinary-derived human chorionic gonadotropin/epidermal growth factor (uhCG/EGF; Pregnyl; Organon, Jersey City, NJ) added to standard aGVHD therapy
Study: 37279855
Drug: Standard aGVHD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard aGVHD therapy (methylprednisolone 48 mg/m2)
Study: 37279999
Drug: Letermovir, 480
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letermovir, 480 mg, orally daily (with acyclovir)
Study: 37279999
Drug: Valganciclovir, 900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valganciclovir, 900 mg, orally daily (adjusted for kidney function)
Study: 37280022
Drug: Bedtime diuretics
Normalized name: Buckley's Bedtime Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bedtime diuretics
Study: 37280022
Drug: Non-diuretics
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-diuretics
Study: 37280082
Drug: Pectoserratus and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pectoserratus and interpectoral plane block combined with general anesthesia (ropivacaine 3.75 mg/mL and clonidine 3.75 µg/mL in 40 mL of 0.9% sodium chloride)
Study: 37280083
Drug: 24-hour group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24-hour group (last dose at 07:00 the day prior to surgery)
Study: 37280083
Drug: 36-hour group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: 36-hour group (last dose at 19:00 2 days prior to surgery)
Study: 37280275
Drug: Gemcitabine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine plus cisplatin (GP) chemotherapy combined with immunotherapy
Study: 37280584
Drug: 12-week remote
Normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12-week remote supervised videoconference-based intervention, consisting of 2 weekly 45-min group sessions with progressive resistance exercises
Study: 37280643
Drug: Delpazolid 0
Normalized name: Delpazolid
DrugBank: Delpazolid (DB13077)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delpazolid 0 mg once daily for 16 weeks
Study: 37280643
Drug: Delpazolid 400
Normalized name: Delpazolid
DrugBank: Delpazolid (DB13077)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delpazolid 400 mg once daily for 16 weeks
Study: 37280643
Drug: Delpazolid 800
Normalized name: Delpazolid
DrugBank: Delpazolid (DB13077)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delpazolid 800 mg once daily for 16 weeks
Study: 37280643
Drug: Delpazolid 1200
Normalized name: Delpazolid
DrugBank: Delpazolid (DB13077)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delpazolid 1200 mg once daily for 16 weeks
Study: 37280643
Drug: Delpazolid 800
Normalized name: Delpazolid
DrugBank: Delpazolid (DB13077)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delpazolid 800 mg twice daily for 16 weeks
Study: 37280688
Drug: Lovastatin (LOV)
Normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lovastatin (LOV) 200 mg
Study: 37282666
Drug: Pralsetinib 400-mg
Normalized name: pralsetinib
DrugBank: Pralsetinib (DB15822)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pralsetinib 400-mg once-daily oral
Study: 37282797
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (conventional speech therapy and singing intervention)
Study: 37283558
Drug: Weaning policy/protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weaning policy/protocol based on duration of opioid/sedative use
Study: 37283558
Drug: IWS policy/protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: IWS policy/protocol for patients on opioids/sedatives ≥ 72 hours
Study: 37283627
Drug: Ivermectin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivermectin (200 μg/kg, single oral dose)